“I’d go on a hike with my kids… that would make me feel so happy.” Recognising what people with haemophilia B identify as meaningful when considering personal goals and the potential for gene therapy
By:
References
- Iorio A, Stonebraker JS, Chambost H, et al.; Data and Demographics Committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries.
Ann Intern Med 2019; 171(8): 540–546. doi:10.7326/M19-1208 . - Di Michele DM, Gibb C, Lefkowitz JM, Ni Q, Gerber LM, Ganguly A. Severe and moderate haemophilia A and B in US females.
Haemophilia 2014; 20(2): e136–43. doi:10.1111/hae.12364 . - Blanchette VS, Key NS, Ljung LR, et al.; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH.
J Thromb Haemost 2014; 12(11): 1935–9. doi:10.1111/jth.12672 . - Srivastava A, Santagostino E, Dougall A, et al. Guidelines for the management of hemophilia, 3rd edition.
Haemophilia 2020; 26 (Suppl 6): 1–158. doi:10.1111/j.1365-2516.2012.02909.x . - O’Hara J, Walsh S, Camp C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life.
Health Qual Life Outcomes 2018;16(1): 84. doi:10.1186/s12955-018-0908-9 . - Cavazza, M., Kodra, Y., Armeni, P. et al. Social/economic costs and quality of life in patients with haemophilia in Europe.
Eur J Health Econ 2016; 17 (Suppl 1): 53–65. doi:10.1007/s10198-016-0785-2 . - Brod M, Bushnell DM, Neergaard JS, et al. Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM).
J Patient Rep Outcomes 2023; 7: 17. doi:10.1186/s41687/s4187-023-00550-6 . - Buckner TW, Batt K, Quon D, et al. Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study.
Eur J Haematol 2018; 100: 5–13. doi:10.1111/ejh.13027 . - Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
N Engl J Med 2007; 357(6): 535–544. doi:10.1056/NEJMoa067659 . - Thornburg CD. Physicians’ perceptions of adherence to prophylactic clotting factor infusions.
Haemophilia 2008; 14(1): 25–9. doi:10.1111/j.1365-2516.2007.01591.x . - Mattis S, Barry V, Taylor N, et al. Disease-related distress among adults with haemophilia: A qualitative study.
Haemophilia 2019; 25(6): 988–995. doi:10.1111/hae.13850 . - Wiley RE, Khoury CP, Snihur AWK, et al. From the voices of people with haemophilia A and their caregivers: Challenges with current treatment, their impact on quality of life and desired improvements in future therapies.
Haemophilia 2019; 25(3): 433–440. doi:10.1111/hae.13754 . - Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update.
Haemophilia 2022; 28(Suppl 4): 103–110. doi:10.1111/hae.14524 . - Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing.
Lancet 2021; 397(10274): 630–640. doi:10.1016/S0140-6736(20)32722-7 . - Ucero-Lozano R, Pérez-Llanes R, Cuesta-Barriuso R et al. Changes in quality of life, adherence, and kinesiophobia in patients with hemophilia treated with extended half-life treatment: Final results of the LongHest Project.
Pharmaceuticals (Basel) 2024 J; 17(7): 835. doi:10.3390/ph17070835 . - Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A.
N Engl J Med 2020; 383(11): 1018–1027. doi:10.1182/blood.2019001292 . - Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B.
N Engl J Med 2023; 388(8): 706–718. doi:10.1056/NEJMoa2211644 . - Shah J, Kim H, Sivamurthy K, et al. Comprehensive analysis and prediction of long-term durability of factor IX activity following tranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Curr Med Res Opin 2023; 39(2): 227–237. doi:10.1080/03007995.2022.2133492 . - Mahlangu J, Kaczmarek R, DA von, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A.
N Engl J Med 2023; 388(8): 694–705. doi:10.1056/NEJMoa2211075 . - Pierce GF, Herzog RW. Two gene therapies for hemophilia available: now what?
Mol Ther 2023; 31(4): 919–920. doi:10.1016/j.ymthe.2023.03.001 . - Valentino LA, Blanchette V, Negrier C, et al. Personalising haemophilia management with shared decision making.
J Haem Pract 2021; 8(1): 69–79. doi:10.17225/jhp00178 . - Fletcher S, Jenner K, Pembroke L, et al. The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study.
Orphanet J Rare Dis 2022; 17(1): 155. doi:10.1186/s13023-022-02256-2 . - Fletcher S, Jenner K, Holland M, et al. Barriers to gene therapy, understanding the concerns people with haemophilia have: an exigency sub-study.
Orphanet J Rare Dis 2024; 19(1): 59. doi:10.1186/s13023-024-03068-2 . - Owen H.
Open Space Technology: A User’s Guide . 3rd edn. San Francisco: Berrett-Koehler Publishers, Inc.; 2008. - Wang M, Negrier C, Driessler F, et al. The hemophilia gene therapy patient journey: Questions and answers for shared decision-making.
Patient Prefer Adherence 2022; 16: 1439–1447. doi:10.2147/PPA.S355627 . - UKRI Medical Research Council; NHS Health Research Authority. Is my study research? Available from
https://www.hra-decisiontools.org.uk/research/ (accessed 01/07/2024). - Glaser BG and Strauss AL.
The Discovery of Grounded Theory: Strategies for Qualitative Research . New York: Aldine Publishing Company; 1967. - Charmaz K.
Constructing Grounded Theory . 2nd edition. Introducing Qualitative Methods series. London: SAGE Publications; 2014. - Gorman R, Woollard L. Is it time for patient involvement in Haemophilia?
Haemophilia 2022; 28(3): e73–e74. doi:10.1111/hae.14520 . - Iorio A, Skinner MW, Clearfield E, et al. Core outcome set for gene therapy in haemophilia: results of the coreHEM multistakeholder project.
Haemophilia 2018; 24(4): e167–72. doi:10.1111/hae.13504 . - Woolley KL, Stones SR, Stephens R, et al. Patient authorship of medical research publications: An evolution, revolution, and solution?
Learned Publishing 2024; 37: e1607. doi:10.1002/leap.1607 . - Baas L, Meijer K, Bredenoord AL, van der Graaf R. What is a cure through gene therapy? An analysis and evaluation of the use of “cure”.
Med Health Care Philos 2024. doi:10.1007/s11019-024-10223-w . Epub ahead of print. - Krumb E, Hermans C. Living with a “hemophilia-free mind” – the new ambition of hemophilia care?
Res Pract Thromb Haemost 2021; 5(5): e12567. doi:10.1002/rth2.12567 . - Hermans C, Pierce GF. Towards achieving a haemophilia-free mind.
Haemophilia 2023; 29(4): 951–953. doi:10.1111/hae.14807 . - Hughes T, Brok-Kristensen, Gargeya Y, et al. “What more can we ask for?”: an ethnographic study of challenges and possibilities for people living with haemophilia.
J Haem Pract 2020; 7(1): 25–36. doi:10.17225/jhp00151 . - Hughes T, Brok-Kristensen M, Gargeya Y, et al. “He’s a normal kid now”: an ethnographic study of challenges and possibilities in a new era of haemophilia care.
J Haem Pract 2020; 7(1): 150–157. doi:10.17225/jhp00167 . - O’Hara J, Martin AP, Nugent D, et al. Evidence of a disability paradox in patient-reported outcomes in haemophilia.
Haemophilia 2021; 27(2): 245–252. doi:10.1111/hae.14278 . - Albrecht GL, Devlieger PJ. The disability paradox: high quality of life against all odds.
Soc Sci Med 1999; 48(8): 977–88. doi:10.1016/s0277-9536(98)00411-0 . - Shakespeare T. The social model of disability. In: Davis LJ (ed.).
The Disability Studies Reader . 2nd ed. New York: Routledge; 2006. pp.197–204. - Goering S. Rethinking disability: the social model of disability and chronic disease.
Curr Rev Musculoskeletal Med 2015; 8(2): 134–138. doi:10.1007/s12178-015-9273-z . - Gorman R. Disabilities and geography. In: Warf B(ed.).
The Encyclopedia of Human Geography . Springer; 2024. doi:10.1007/978-3-031-25900-5 - Berntorp E, LeBeau P, Ragni MV, et al. Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain.
Haemophilia 2022; 28(3): 453–461. doi:10.1111/hae.14525 . - Barlow JH, Stapley J, Ellard DR. Living with haemophilia and von Willebrand’s: A descriptive qualitative study.
Patient Educ Couns 2007; 68(3): 235–42. doi:0.1016/j.pec.2007.06.006 . - Baas L, van der Graaf R, van Hoorn ES, et al. The ethics of gene therapy for hemophilia: a narrative review.
J Thromb Haemost 2023; 21(3): 413–420. doi:10.1016/j.jtha.2022.12.027 . - NICE. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B. Technology appraisal guidance. TA989. Published 24 July 2024.
https://www.nice.org.uk/guidance/TA989 (Accessed 19 October 2024).
DOI: https://doi.org/10.2478/jhp-2025-0001 | Journal eISSN: 2055-3390
Language: English
Page range: 1 - 14
Published on: Mar 19, 2025
Published by: Haemnet Ltd
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Related subjects:
© 2025 Kate Khair, Ranjit Nagra, Richard Gorman, Simon Fletcher, Kathryn Jenner, Joe Trim, Shuk-Li Collings, published by Haemnet Ltd
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.